title: Differential rates of ischemic cholangiopathy and graft survival associated with induction therapy in DCD liver transplantation.
abstract: Transplantation utilizing donation after circulatory death (DCD) donors is associated with ischemic cholangiopathy (IC) and graft loss. The University of Washington (UW) DCD experience totals 89 DCD liver transplants performed between 2003 and 2011. Overall outcome after DCD liver transplantation at UW demonstrates Kaplan-Meier estimated 5-year patient and graft survival rates of 81.6% and 75.6%, respectively, with the great majority of patient and graft losses occurring in the first-year posttransplant from IC. Our program has almost exclusively utilized either anti-thymocyte globulin (ATG) or basiliximab induction (86/89) for DCD liver transplantations. Analysis of the differential effect of induction agent on graft survival demonstrated graft survival of 96.9% at 1 year for ATG versus 75.9% for basiliximab (p = 0.013). The improved survival did not appear to be from a lower rate of rejection (21.9% vs. 22.2%) but rather a differential rate of IC, 35.2% for basiliximab versus 12.5% for ATG (p = 0.011). Multivariable analysis demonstrated induction agent to be independently associated with graft survival and IC free graft survival when analyzed against variables including donor age, fWIT, donor cold ischemia time and transplant era.
authors.affiliation: Division of Transplantation, University of California, San Diego, CA.
authors.forename: J B
authors.initials: JB
authors.lastname: Halldorson
authors.forename: R
authors.initials: R
authors.lastname: Bakthavatsalam
authors.forename: M
authors.initials: M
authors.lastname: Montenovo
authors.forename: A
authors.initials: A
authors.lastname: Dick
authors.forename: S
authors.initials: S
authors.lastname: Rayhill
authors.forename: J
authors.initials: J
authors.lastname: Perkins
authors.forename: J
authors.initials: J
authors.lastname: Reyes
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D000077552:Basiliximab; D001649:Bile Duct Diseases / Q000453:epidemiology*; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000139:chemically induced / Q000401:mortality; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D007511:Ischemia / Q000453:epidemiology*; D008107:Liver Diseases / Q000601:surgery; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011379:Prognosis; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors; D014019:Tissue Donors; D009927:Tissue and Organ Procurement; D014481:United States / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab
keywords: Clinical research/practice; donors and donation: donation after circulatory death (DCD); fusion proteins and monoclonal antibodies: basiliximab/daclizumab; immunosuppressant; immunosuppression/immune modulation; immunosuppressive regimens; induction; ischemia reperfusion injury (IRI); liver transplantation/hepatology; polyclonal preparations: rabbit antithymocyte globulin